ADIPOQ and polycystic ovary syndrome: The results of this study will not only bridge a critical gap in understanding the genetic architecture of metabolic dysfunction in PCOS but also underscore the potential of ADIPOQ genotyping for personalized risk stratification, paving the way for novel therapeutic strategies targeting the adiponectin pathway in this prevalent endocrine disorder.